Global Haematologic Malignancies Treatment Market Report and Forecast 2025-2034

Global Haematologic Malignancies Treatment Market Outlook

The global haematologic malignancies treatment market reached a value of USD 70.30 billion in 2024. The market is further expected to grow at a CAGR of 10.5% in the forecast period of 2025-2034 to reach a value of USD 172.57 billion by 2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Demand for Chemotherapy to Augment the Haematologic Malignancies Treatment Industry Growth

Based on therapy, the chemotherapy segment accounts for a significant share in the haematologic malignancies treatment industry and is expected to grow further at a healthy pace over the forecast period. Chemotherapy is a treatment for various blood cancers that involves the use of a mixture of medicines to fight cancer cells by preventing them from multiplying and developing. Chemotherapy reduces tumours and allows surgical excision of cancer in people with malignancies that are only marginally resectable. Over the forecast period, this is likely to drive the revenue growth in the chemotherapy segment.

Asia Pacific to Provide Enhanced Growth Opportunities to the Hematologic Malignancies Treatment Industry

Region-wise, Asia Pacific is expected to witness a robust growth over the forecast period and hold a significant share of the market by 2026. The rapid development of advanced healthcare facilities, the rising incidences of blood cancer, increased awareness of early diagnostic and treatment approaches, and a growing focus on meeting unmet clinical needs of patients in countries throughout the region are the major factors that are expected to contribute to the growth of the haematologic malignancies treatment industry in the region.

Haematologic Malignancies Treatment: Market Segmentation

Cancers of the blood, bone marrow, and lymph nodes are known as haematologic malignancies. Acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), myeloma, and lymphoma (Hodgkin's and non-Hodgkin’s (NHL)) are all included in this categorisation. The commonly suggested treatment methods for haematologic malignancies are chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation, among others.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By type, the market is divided into:

• Leukaemia
• Lymphoma
• Multiple Myaeloma
• Others

Among these, the leukaemia segment is further classified based on type into acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myeloid leukaemia, and chronic myeloid leukaemia.

Based on therapy, the industry can be segmented into:

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Growing Prevalence of Haematologic Malignancies to Bolster the Growth of the Hematologic Malignancies Treatment Industry

The haematologic malignancies treatment industry is seeing a healthy growth due to the rising number of incidences of haematologic malignancies. Moreover, rising investment in the development of physiologically effective medicines, as well as a favourable reimbursement scenario, are fuelling the market growth. Furthermore, the market expansion is being propelled by substantial research and development efforts, a robust product pipeline, and a rising number of product releases over the years.

Over the forecast period, the rapidly growing geriatric population throughout the world is expected to be a key driver of the market growth because the elderly are at a greater risk of haematologic malignancies.

Key Industry Players in the Global Haematologic Malignancies Treatment Market

The report gives a detailed analysis of the following key players in the global haematologic malignancies treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi
• AbbVie Inc.
• Novartis AG
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report